Trial Profile
A PHASE 1, SINGLE DOSE OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF LORLATINIB IN SUBJECTS WITH IMPAIRED RENAL FUNCTION
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Cancer; Lymphoma; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Jan 2022 Results assessing impact of varying degrees of renal impairment on the safety and pharmacokinetics of lorlatinib published in the European Journal of Drug Metabolism and Pharmacokinetics
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 19 Mar 2020 Status changed from recruiting to completed.